ARS | Publication request: Use of inactivated E.Coli enterotoxins to enhance respiratory mucosal adjuvanticity during vaccination in swine

Submitted to: Clinical and Vaccine Immunology
Publication Type: Peer Reviewed Journal
Publication Acceptance Date: September 1, 2011
Publication Date: September 14, 2011
Citation: Barrette, R.W., Rood, D., Challa, S., Szczepanek, S.M., Avery, N., Vajdy, M., Kramer, E., Rodriguez, L.L., Silbart, L.K. 2011. Use of inactivated E.Coli enterotoxins to enhance respiratory mucosal adjuvanticity during vaccination in swine. Clinical and Vaccine Immunology. 18(11):1996-1998.

Interpretive Summary: Foot-and-mouth disease (FMD) is a devastating disease of livestock, decreasing animal productivity and disrupting trade of millions of animals, particularly in developing countries. Currently available vaccines are effective in preventing clinical disease but do not always protect against infection. This is thought to be the result of poor induction of immunity by these vaccines on the mucosal membranes overlaying the respiratory and digestive tracts. This work reports the application of detoxified bacterial enterotoxins as mucosal adjuvants in pigs, in order to increase mucosal immunity. Administration of these adjuvants enhanced mucosal immunity in nasal wash samples when compared to controls. This work will be useful not only for improving FMD, but is also relevant to the general field of vaccines and to the enhancement of mucosal immunity.

Technical Abstract: In order to augment responses to respiratory vaccines in swine, various adjuvants were intranasally co-administered with an antigen to pigs. Detoxified E. coli enterotoxins LTK63 and LTR72 enhanced mucosal and systemic immunity to the model peptide, exhibiting their efficacy as mucosal adjuvants for non-replicating antigens upon intranasal immunization in swine.